{"id":"actarit","rwe":[{"pmid":"40958732","year":"2025","title":"Employing cancer driver genes for the identification of immunological features in two esophageal cancer subtypes to facilitate immunotherapy.","finding":"","journal":"Immunopharmacology and immunotoxicology","studyType":"Clinical Study"},{"pmid":"40708267","year":"2025","title":"Amide-Enabled Distal and Multiple Dehydrogenative C-H Alkynylation with Tuning Site Selectivity.","finding":"","journal":"Organic letters","studyType":"Clinical Study"},{"pmid":"38675141","year":"2024","title":"Ionic Liquid Transdermal Patches of Two Active Ingredients Based on Semi-Ionic Hydrogen Bonding for Rheumatoid Arthritis Treatment.","finding":"","journal":"Pharmaceutics","studyType":"Clinical Study"},{"pmid":"34489018","year":"2021","title":"Biosynthesis of actarit using engineered Escherichia coli.","finding":"","journal":"Enzyme and microbial technology","studyType":"Clinical Study"},{"pmid":"33717783","year":"2021","title":"Emphysematous cystitis in a patient using immunosuppressant agents.","finding":"","journal":"Journal of general and family medicine","studyType":"Clinical Study"}],"tags":[{"label":"actarit","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Antirheumatic Agents","category":"pharmacology"}],"phase":"phase_2","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"p-acetamidophenylacetic acid","offLabel":[],"synonyms":["actarit","p-Acetamidophenylacetic acid"],"timeline":[],"brandName":"P-Acetamidophenylacetic Acid","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"actarit","explanation":"Imagine your body's cells are like a orchestra, and ACTARIT is like a conductor that helps the cells work together in harmony. By influencing the way cells communicate and respond to signals, ACTARIT may help to regulate various bodily functions. However, the precise way in which it does this is still a mystery.","oneSentence":"ACTARIT is thought to work by modulating a specific biological pathway, although the exact details of its mechanism are not well understood.","technicalDetail":"ACTARIT is a small molecule that binds to a specific protein or receptor, triggering a cascade of downstream effects that ultimately lead to its therapeutic effects."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/84","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ACTARIT","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ACTARIT","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:26:23.653521","biosimilars":[],"competitors":[],"genericName":"actarit","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03660059","phase":"PHASE3","title":"A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)","status":"COMPLETED","sponsor":"Astellas Pharma China, Inc.","startDate":"2018-09-27","conditions":["Rheumatoid Arthritis (RA)"],"enrollment":385,"completionDate":"2021-11-02"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"HW5B6351RZ","CHEBI":"CHEBI:31173","INN_ID":"6549","UMLSCUI":"C0378042","ChEMBL_ID":"CHEMBL1885632","KEGG_DRUG":"D01395","PUBCHEM_CID":"2018","MESH_SUPPLEMENTAL_RECORD_UI":"C052562"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"2025 Oct","pmid":"40958732","title":"Employing cancer driver genes for the identification of immunological features in two esophageal cancer subtypes to facilitate immunotherapy.","journal":"Immunopharmacology and immunotoxicology"},{"date":"2025 Aug 8","pmid":"40708267","title":"Amide-Enabled Distal and Multiple Dehydrogenative C-H Alkynylation with Tuning Site Selectivity.","journal":"Organic letters"},{"date":"2024 Apr 1","pmid":"38675141","title":"Ionic Liquid Transdermal Patches of Two Active Ingredients Based on Semi-Ionic Hydrogen Bonding for Rheumatoid Arthritis Treatment.","journal":"Pharmaceutics"},{"date":"2021 Oct","pmid":"34489018","title":"Biosynthesis of actarit using engineered Escherichia coli.","journal":"Enzyme and microbial technology"},{"date":"2021 Mar","pmid":"33717783","title":"Emphysematous cystitis in a patient using immunosuppressant agents.","journal":"Journal of general and family medicine"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"P-Acetamidophenylacetic Acid is a small molecule with various synonyms, including Actarit, Mirabegron, and others. Its exact mechanism and clinical uses are not specified in the provided information, but it is listed as a compound with a modality of small molecule.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}